文献速递系统性红斑狼疮其他结缔组织病

BCMA靶向CAR-T治疗难治性SLE与SSc的1期试验

B cell Maturation Antigen Targeted Chimeric Antigen Receptor T Cell Therapy for Refractory Systemic Lupus Erythematosus and Systemic Sclerosis.
PubMed 文献 · Arthritis Rheumatol · 2026-05-07

该进行中的1期试验评估了BCMA靶向CAR-T疗法HBI0101在6例重度难治性系统性红斑狼疮(n=3)或系统性硬化症(n=3)患者中的安全性与初步疗效。中位随访6个月,观察到可接受的安全性特征及早期临床活性,支持进一步前瞻性评估。

要点

  • 3-4级中性粒细胞减少见于2例,经支持治疗管理。
  • 细胞因子释放综合征见于5例(2级3例、1级2例),无ICANS。
  • SLE中2例SLEDAI-2K降至0、1例降至4;SSc中3例皮肤受累均改善。

核心结论

  • HBI0101在重度难治性SLE或SSc患者中显示可接受的安全性特征和早期临床活性。

研究设计与样本

  • 进行中的1期试验,纳入6例重度SLE(n=3)或SSc(n=3)患者,中位年龄41岁(范围21-65),中位病程2.7年(范围1.1-20.5),既往中位3.5线免疫调节治疗(范围2-9),中位随访6个月(范围6-9)。

主要发现

  • 3-4级中性粒细胞减少发生于2例,经支持治疗管理;3例出现低丙种球蛋白血症需静脉注射免疫球蛋白替代。
  • 细胞因子释放综合征发生于5例(2级3例、1级2例),1例未发生;未观察到免疫效应细胞相关神经毒性综合征。
  • SLE中2例SLEDAI-2K降至0、1例降至4;SSc中3例皮肤受累均改善,改良Rodnan皮肤评分和EUSTAR活动指数下降。

关键数值与推荐

  • SLE疗效以SLEDAI-2K评估:2例降至0,1例降至4。
  • SSc疗效以改良Rodnan皮肤评分和EUSTAR活动指数评估:3例均显示下降。

临床怎么用

  • 对于重度难治性SLE或SSc,BCMA靶向CAR-T可作为探索性治疗选择,需在临床试验框架内评估。
  • 治疗期间需监测中性粒细胞减少、低丙种球蛋白血症和细胞因子释放综合征,并给予相应支持治疗。

局限性

  • 样本量小(共6例),随访时间短(中位6个月),为进行中的1期试验,疗效需进一步前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the safety and preliminary efficacy of HBI0101, B cell maturation antigen targeted chimeric antigen receptor T cell therapy, in patients with severe refractory systemic lupus erythematosus or systemic sclerosis. METHODS: We conducted an ongoing phase 1 trial of HBI0101 in six patients with severe systemic lupus erythematosus (n = 3) or systemic sclerosis (n = 3). The median age was 41 years (range: 21-65), the median disease duration was 2.7 years (range: 1.1-20.5), and patients had received a median of 3.5 previous lines of immunomodulatory therapy (range: 2-9). The median follow-up was six months (range: 6-9). RESULTS: Grade 3 to 4 neutropenia occurred in two patients and was managed with supportive care. Three patients had hypogammaglobulinemia requiring intravenous immunoglobulin replacement. Cytokine release syndrome occurred in five patients (grade 2 in three and grade 1 in two) and was absent in one patient. No immune effector cell-associated neurotoxicity syndrome was observed. In systemic lupus erythematosus, the Systemic Lupus Erythematosus Disease Activity Index 2000 decreased to 0 in two patients and to 4 in one patient. In systemic sclerosis, skin involvement improved in all three patients with reductions in modified Rodnan skin score and European Scleroderma Trials and Research activity indices. CONCLUSION: HBI0101 demonstrated an acceptable safety profile and early clinical activity in patients with severe refractory systemic lupus erythematosus or systemic sclerosis, supporting further prospective evaluation.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Kfir-Erenfeld S, Elias S, Asherie N, et al. B cell Maturation Antigen Targeted Chimeric Antigen Receptor T Cell Therapy for Refractory Systemic Lupus Erythematosus and Systemic Sclerosis. Arthritis Rheumatol. 2026. PMID: 42098533. doi:10.1002/art.70211

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。